Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
The therapeutic dose range of fluticasone propionate for asthma in
adolescents and adults should be revised downwards from the currently
recommended 200-2000 µg/day. Holt et al's meta-analysis (p 253) of
randomised controlled trials, which included over 2300 adults and
adolescents with moderate to severe asthma, shows that most of the
efficacy of fluticasone is achieved at a dose of 100-250 µg/day, with
a maximum effect at around 500 µg/day. These findings applied to all
clinical outcomes, including exacerbations. The study also partially
explains why adding a long acting
agonist is more efficacious than
increasing the dose of fluticasone beyond 500 µg/day.